Following its approval, the FDA-approved anti-PD-1 (Nivolumab and Pembrolizumab) and anti-PD-L1 (Atezolizumab) ICIs in 2014 and 2015 after positive trials in advanced-stage melanoma, renal cell carcinoma, and NSCLC patients [61,62] (Figure 2). Here, CD274 is linked to non-small cell lung carcinoma.